Christian Hagel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7428755/publications.pdf

Version: 2024-02-01

82	2,120	361413	243625
papers	citations	20	44
		h-index	g-index

83	83	83	3998
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial. European Journal of Cancer, 2022, 164, 30-38.	2.8	3
2	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
3	Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Morphological and Immunohistochemical Study. Anticancer Research, 2022, 42, 1247-1261.	1.1	3
4	Tissue Microarray Analyses Suggest Axl as a Predictive Biomarker in HPV-Negative Head and Neck Cancer. Cancers, 2022, 14, 1829.	3.7	2
5	Oral HRAS Mutation in Orofacial Nevus Sebaceous Syndrome (Schimmelpenning-Feuerstein-Mims-Syndrome): A Case Report With a Literature Survey. In Vivo, 2022, 36, 274-293.	1.3	3
6	ERBB2 and ERBB3 Growth Factor Receptors, Neuregulin-1, CD44 and Ki-67 Proliferation Index in Neurofibromatosis Type 1-associated Peripheral Nerve Sheath Tumors. Anticancer Research, 2022, 42, 2327-2340.	1.1	2
7	Registration of histological brain images onto optical coherence tomography images based on shape information. Physics in Medicine and Biology, 2022, 67, 135007.	3.0	8
8	HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.. Neuro-Oncology, 2022, 24, i63-i64.	1.2	1
9	EPEN-27. Epigenetic dissection of spinal ependymomas (SP-EPN) separates tumors with and withoutNF2 mutation. Neuro-Oncology, 2022, 24, i44-i45.	1.2	0
10	Co-expression of intermediate filaments glial fibrillary acidic protein and cytokeratin in pituitary adenoma. Pituitary, 2021, 24, 62-67.	2.9	2
11	A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 141, 217-233.	7.7	33
12	Neurofibromatosis Type 1 With Cherubism-like Phenotype, Multiple Osteolytic Bone Lesions of Lower Extremities, and Alagille-syndrome: Case Report With Literature Survey. In Vivo, 2021, 35, 1711-1736.	1.3	3
13	Clinical Presentation and Disease Course of 37 Consecutive Cases of Progressive Multifocal Leukoencephalopathy (PML) at a German Tertiary-Care Hospital: A Retrospective Observational Study. Frontiers in Neurology, 2021, 12, 632535.	2.4	12
14	Microdont Developing Outside the Alveolar Process and Within Oral Diffuse and Plexiform Neurofibroma in Neurofibromatosis Type 1. Anticancer Research, 2021, 41, 2083-2092.	1.1	3
15	Neurofibromatosis type 2 predisposes to ependymomas of various localization, histology, and molecular subtype. Acta Neuropathologica, 2021, 141, 971-974.	7.7	12
16	Differential expression of stem cell markers in proliferating cells in glioma. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2969-2982.	2.5	8
17	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
18	Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis. Endocrine Pathology, 2021, 32, 473-479.	9.0	1

#	Article	IF	Citations
19	Double adenomas of the pituitary reveal distinct lineage markers, copy number alterations, and epigenetic profiles. Pituitary, 2021, 24, 904-913.	2.9	4
20	Neuropathology associated with SARS-CoV-2 infection. Lancet, The, 2021, 397, 276.	13.7	13
21	Long-term Follow-up and Histological Correlation of Peripheral Nervous System Alterations in Neurofibromatosis TypeÂ2. Clinical Neuroradiology, 2021, , 1.	1.9	4
22	Analysis of Intracerebroventricular (ICV) Device Function and Integrity under Long-Term ICV-ERT in CLN2 Patients. Neuropediatrics, 2021, 52, .	0.6	0
23	PATH-34. MOLECULAR AND CLINICAL HETEROGENEITY WITHIN SPINAL EPENDYMOMAS. Neuro-Oncology, 2021, 23, vi122-vi122.	1.2	0
24	Distinctive low epidermal nerve fiber density in schwannomatosis patients provides a major parameter for diagnosis and differential diagnosis. Brain Pathology, 2020, 30, 386-391.	4.1	4
25	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. Acta Neuropathologica, 2020, 139, 403-406.	7.7	9
26	Lingual Mandibular Bone Depression. In Vivo, 2020, 34, 2527-2541.	1.3	4
27	Mosaic Neurofibromatosis Type 1 With Multiple Cutaneous Diffuse and Plexiform Neurofibromas of the Lower Leg. Anticancer Research, 2020, 40, 3423-3427.	1.1	3
28	Mutations of the gene FNIP1 associated with a syndromic autosomal recessive immunodeficiency with cardiomyopathy and preâ€excitation syndrome. European Journal of Immunology, 2020, 50, 1078-1080.	2.9	17
29	Contribution of mTOR and PTEN to Radioresistance in Sporadic and NF2-Associated Vestibular Schwannomas: A Microarray and Pathway Analysis. Cancers, 2020, 12, 177.	3.7	13
30	Susceptibility to cellular stress in PS1 mutant N2a cells is associated with mitochondrial defects and altered calcium homeostasis. Scientific Reports, 2020, 10, 6455.	3.3	6
31	Null phenotype of neurofibromatosis type 1 in a carrier of a heterozygous atypical NF1 deletion due to mosaicism. Human Mutation, 2020, 41, 1226-1231.	2.5	3
32	Lack of astrocytes hinders parenchymal oligodendrocyte precursor cells from reaching a myelinating state in osmolyte-induced demyelination. Acta Neuropathologica Communications, 2020, 8, 224.	5.2	14
33	C-Fiber Loss as a Possible Cause of Neuropathic Pain in Schwannomatosis. International Journal of Molecular Sciences, 2020, 21, 3569.	4.1	5
34	PATH-07. QUALITY ASSURANCE IN CEREBROSPINAL FLUID CYTOLOGY ASSESSMENT FOR MEDULLOBLASTOMA STAGING LEADS TO POTENTIAL IMPROVED RISK-GROUP ASSESSMENT IN THE PROSPECTIVE MULTICENTER HIT-2000 TRIAL. Neuro-Oncology, 2020, 22, iii425-iii426.	1.2	1
35	MBCL-09. ISOLATED M1 METASTASES IN PEDIATRIC MEDULLOBLASTOMA: IS POSTOPERATIVE RADIOTHERAPY FOLLOWED BY MAINTENANCE CHEMOTHERAPY SUPERIOR TO POSTOPERATIVE SANDWICH-CHEMOTHERAPY AND RADIOTHERAPY?. Neuro-Oncology, 2020, 22, iii389-iii389.	1.2	0
36	Cerebral cavernomas in adults and children express relaxin. Journal of Neurosurgery: Pediatrics, 2020, 25, 144-150.	1.3	2

#	Article	IF	Citations
37	Early-onset stroke in two siblings with Neurofibromatosis type 1. European Journal of Medical Genetics, 2019, 62, 103710.	1.3	4
38	Mice deficient in the lysosomal enzyme palmitoyl-protein thioesterase 1 (PPT1) display a complex retinal phenotype. Scientific Reports, 2019, 9, 14185.	3.3	17
39	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	3.6	29
40	Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. Neuro-Oncology, 2019, 21, 508-516.	1.2	32
41	Painful Vater-Pacini neuroma of the digit in neurofibromatosis type 1. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2019, 8, Doc03.	0.1	2
42	Coâ€occurrence of schwannomatosis and rhabdoid tumor predisposition syndrome 1. Molecular Genetics & Genomic Medicine, 2018, 6, 627-637.	1.2	13
43	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. Acta Neuropathologica, 2018, 136, 293-302.	7.7	56
44	Neuropathies in the setting of Neurofibromatosis tumor syndromes: Complexities and opportunities. Experimental Neurology, 2018, 299, 334-344.	4.1	22
45	Pigmented (melanotic) diffuse neurofibroma of the back in neurofibromatosis type 1. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2018, 7, Doc04.	0.1	0
46	Historical documents on epilepsy: From antiquity through the 20th century. Brain and Development, 2017, 39, 457-463.	1.1	20
47	Immunoprofiling of glial tumours of the neurohypophysis suggests a common pituicytic origin of neoplastic cells. Pituitary, 2017, 20, 211-217.	2.9	26
48	Pilomatrixoma of the Neck/Shoulder Region Mimicking a Rapidly Growing Neoplasm of Peripheral Nerve Sheath Origin in Neurofibromatosis Type 1. Anticancer Research, 2017, 37, 6907-6910.	1.1	2
49	Retinal Degeneration in Mice Deficient in the Lysosomal Membrane Protein CLN7. , 2016, 57, 4989.		26
50	Recurrent multilocular mandibular giant cell granuloma in neurofibromatosis type 1: Evidence for second hit mutation of NF1 gene in the jaw lesion and treatment with curettage and bone substitute materials. Journal of Cranio-Maxillo-Facial Surgery, 2016, 44, 1054-1060.	1.7	10
51	The importance of nerve microenvironment for schwannoma development. Acta Neuropathologica, 2016, 132, 289-307.	7.7	62
52	Mannose 6-phosphate-dependent targeting of lysosomal enzymes is required for normal craniofacial and dental development. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 1570-1580.	3.8	15
53	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
54	CPI-17 drives oncogenic Ras signaling in human melanomas via Ezrin-Radixin-Moesin family proteins. Oncotarget, 2016, 7, 78242-78254.	1.8	27

#	Article	IF	Citations
55	Expression of the Insulin-like Growth Factor-1 Receptor in Odontogenic Myxoma. Anticancer Research, 2016, 36, 3103-7.	1.1	1
56	Expansive Extracranial Growth of Intracranial Meningioma in Neurofibromatosis Type 2. Anticancer Research, 2016, 36, 3161-7.	1.1	0
57	Cerebral Palsy: A Lifelong Challenge Asks for Early Intervention. The Open Neurology Journal, 2015, 9, 45-52.	0.4	30
58	Keratinocytic epidermal nevus syndrome with Schwann cell proliferation, lipomatous tumour and mosaic KRAS mutation. BMC Medical Genetics, 2015, 16, 6.	2.1	18
59	Biological Relevance and Therapeutic Potential of the Hypusine Modification System. Journal of Biological Chemistry, 2015, 290, 18343-18360.	3.4	48
60	Angiolipoma of the sellar region. Pituitary, 2015, 18, 176-178.	2.9	0
61	Upregulation of Shiga Toxin Receptor <scp>CD</scp>77/<scp>G</scp>b3 and Interleukinâ€1Î² Expression in the Brain of <scp>EHEC</scp> Patients with Hemolytic Uremic Syndrome and Neurologic Symptoms. Brain Pathology, 2015, 25, 146-156.	4.1	12
62	Unilateral gynaecomastia in a 16-month-old boy with neurofibromatosis type 1 - case report and brief review of the literature. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2015, 4, Doc11.	0.1	2
63	Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1. Anticancer Research, 2015, 35, 137-44.	1.1	11
64	Vessel and Mast Cell Densities in Sporadic and Syndrome-associated Peripheral Nerve Sheath Tumors. Anticancer Research, 2015, 35, 4713-22.	1.1	4
65	Vascular Innervation in Benign Neurofibromas of Patients with Neurofibromatosis Type 1. Anticancer Research, 2015, 35, 6509-16.	1.1	3
66	Ipsilateral Sphenoid Wing Dysplasia, Orbital Plexiform Neurofibroma and Fronto-Parietal Dermal Cylindroma in a Patient with Segmental Neurofibromatosis. Anticancer Research, 2015, 35, 6813-8.	1.1	6
67	Human Dirofilaria repens infection of the zygomatico-temporal region. Journal of Cranio-Maxillo-Facial Surgery, 2014, 42, 612-615.	1.7	5
68	Familial Alzheimerâ€™s diseaseâ€“associated presenilin-1 alters cerebellar activity and calcium homeostasis. Journal of Clinical Investigation, 2014, 124, 1552-1567.	8.2	104
69	Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma. PLoS ONE, 2014, 9, e94132.	2.5	33
70	Rhinophyma in tuberous sclerosis complex: case report with brief review of literature. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW, 2014, 3, Doc12.	0.1	1
71	Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression. Journal of Neuro-Oncology, 2013, 112, 191-197.	2.9	12
72	Use of Axl, a therapeutic target in AML, to mediate stroma-induced chemoresistance.. Journal of Clinical Oncology, 2013, 31, 7027-7027.	1.6	0

#	Article	IF	Citations
73	Hybrid Neurofibroma/Schwannoma is Overrepresented Among Schwannomatosis and Neurofibromatosis Patients. American Journal of Surgical Pathology, 2012, 36, 702-709.	3.7	109
74	Hyaluronan in intraâ€operative edema of NF1â€associated neurofibromas. Neuropathology, 2012, 32, 406-414.	1.2	7
75	Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2â€associated gliomas to be spinal ependymomas. Neuropathology, 2012, 32, 611-616.	1.2	28
76	Cancer Stem Cell-Like Cells Derived from Malignant Peripheral Nerve Sheath Tumors. PLoS ONE, 2011, 6, e21099.	2.5	43
77	Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma. Journal of Neuro-Oncology, 2011, 103, 239-245.	2.9	21
78	Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncology, 2010, 12, 14-18.	1.2	124
79	Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2007, 82, 187-192.	2.9	76
80	Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 428-432.	6.4	91
81	Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. Acta Neuropathologica, 2002, 104, 179-187.	7.7	53
82	Increased proliferative activity due to necroses induced by pre-operative embolization in benign meningiomas. Journal of Neuro-Oncology, 1998, 40, 257-264.	2.9	13